packagePolatuzumabVedotin

polatuzumab vedotin

Extends from Pharmacolibrary.Interfaces.PartialSubstance (Identity and physicochemical constants of one drug (Drugs.Substances)).

Information

Polatuzumab vedotin is an antibody-based anticancer drug used to treat B-cell lymphoma. It is authorised in the European Union and remains under investigation for further uses.

Summary written by glm-5.3-flash from Wikidata Q19946115 and the WHO ATC classification and the EMA medicines list; not checked by a person.

name:polatuzumab vedotin
ATC codes:L01FX14
DrugBank:DB12240
Wikidata:Q19946115
molar mass:150000 g/mol (Drugs.Common 25.09, not verified)

Metabolites

AcMMAEacMMAEmolar mass unknown
UnconjugatedMMAEunconjugated MMAE718 g/mol (paper)

Parameters

TypeNameDefaultDescription
Stringname (from PartialSubstance)""INN / common name
String[:]atcCodes (from PartialSubstance)fill("", 0)all WHO ATC codes of the drug
StringdrugbankId (from PartialSubstance)""e.g. DB00758
StringpubchemCid (from PartialSubstance)""PubChem compound id
StringchebiId (from PartialSubstance)""ChEBI id (number)
StringwikidataId (from PartialSubstance)""e.g. Q410238
Stringformula (from PartialSubstance)""molecular formula
Modelica.Units.SI.MolarMassM (from PartialSubstance)0molar mass; 0 = unknown
ReallogP (from PartialSubstance)Modelica.Constants.infoctanol-water partition coefficient (log10); inf = unknown

Contents

NameDescription
AcMMAEmetabolite: acMMAE
UnconjugatedMMAEmetabolite: unconjugated MMAE